Hyperphosphatemia
Conditions
Interventions
Blood sampling Administration of ferric citrate hydrate
Sponsors
Shigeru Shibata
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)Patients in adults (over 20 years old) 2)No gender 3)Patients with eGFR (mL / min / 1.73 m 2) calculated from the serum creatinine value of 15 or more and less than 45 and serum phosphorus value of 4.0 mg / dL or more (including patients taking phosphorus adsorbent) 4)Patients whose eGFR (mL / min / 1.73 m 2) calculated from the serum creatinine value is 15 or more and less than 45 and serum phosphorus value is 4.0 mg / dL or more (patients who are taking phosphorus adsorption drugs have no acute renal function change, CKDPatients whose systemic condition is stable as treatment intervention other than administration of phosphorus adsorption is performed according to clinical guide (edited by Japan Society of Nephrology) 5)Patients receiving one or more appropriate nutritional guidance 6)Patients who agreed to participate in the study
Exclusion criteria
Exclusion criteria: 1)Patients contraindicated for administration of ferric citrate hydrate 2)Patients with a history of hypersensitivity to the ingredients of this drug 3)Patients with iron overload such as hemochromatosis 4)Defective diabetes (HbA1c> 9.0%) 5)Uncontrolled hypertension (systolic blood pressure of 170 mmHg or more or diastolic blood pressure of 110 mmHg or more) 6)Acute renal failure, nephrotic syndrome, people who have undergone hemodialysis after kidney transplantation 7)tumor (no recurrence, do not exclude those who are untreated for 5 years) 8)Those who are pregnant, lactating, planning pregnancy during the study 9)Persons who are undergoing or are undergoing hormone therapy (HRT) with estrogen 10)Patient using Cinacalcet (Regala R) 11)Patients who are judged inappropriate by the attending physician (dementia, mental retardation, etc.)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change from eGFR baseline | — |
Secondary
| Measure | Time frame |
|---|---|
| 1)Duration up to 30% decline of eGFR 2)Serum phosphorus level 3)Urinary albumin amount (g / gCre), urinary phosphorus excretion 4)Blood calciprotein particles (CPP), urinary L-FABP 5)FGF23, intact PTH 6)Iron (Fe / TIBC, ferritin) 7)Anemia (Hb) | — |
Contacts
Public Contactakiyama rumi
teikyo university
Outcome results
None listed